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Intraductal Tubular Carcinoma of the
Pancreas: a Case Report with the Imaging
Findings
We describe here a case of intraductal tubular carcinoma of the main pancreat-
ic duct. Gadolinium-enhanced pancreas magnetic resonance (MR) imaging
showed an enhancing mass that was confined in the dilated main pancreatic duct
of the pancreatic body, along with dilatation of the upstream main pancreatic duct
and chronic pancreatitis that was due to obstruction. MR cholangiopancreatogra-
phy and an endoscopic retrograde pancreatogram showed a filling defect that
was due to an intraductal mass of the pancreatic body, along with dilatation of the
upstream main pancreatic duct and no dilatation of the downstream main pancre-
atic duct. The pathological findings demonstrated an intraductal nodular appear-
ance without papillary projection or mucin hypersecretion.
s defined by the World Health Organization (WHO) definition and
grading system, an intraductal tubular carcinoma (ITC) of the pancreas is
classified as a subtype of intraductal papillary mucinous neoplasms
(IPMNs) (1). However, in the General Rules for the study of Pancreatic Cancer
published by the Japan Pancreas Society (2), intraductal tumors of the pancreas are
classified into IPMNs and intraductal tubular tumors (ITTs). ITTs are further divided
into intraductal tubular adenomas (ITAs) and ITCs. To date, only 12 cases of ITCs
have been reported in the clinical literature (3-9). We describe here the imaging
findings of a case of intraductal tubular carcinoma of the pancreas that presented as an
intraductal mass in the dilated main pancreatic duct.
CASE REPORT
A 63-year-old woman presented with abdominal pain and diarrhea for two weeks.
The patient had undergone transabdominal ultrasonography at a local hospital, and
the procedure incidentally demonstrated a dilatated main pancreatic duct in the
pancreatic tail; she was then referred to our hospital for further evaluation. There was
no personal or family history of pancreatic disease. A physical examination revealed
no unusual findings. No elevation of the levels of serum amylase and lipase and such
tumor markers as carbohydrate antigen 19-9 (CA 19-9) were noted on the laboratory
tests.
Contrast-enhanced pancreas computed tomography (CT) showed a moderate dilata-
tion of the main pancreatic duct in the pancreatic tail without an obstructive mass (Fig.
1A). No peripancreatic fatty infiltration or lymph node enlargement was noted.
Magnetic resonance (MR) imaging with MR cholangiopancreatography (MRCP) was
performed to exclude any lesion that could cause obstruction proximal to the dilated
main pancreatic duct. The unenhanced and gadolinium-enhanced pancreas MR images
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Fig. 1. 63-year-old woman with intraductal tubular carcinoma of pancreas that presented as intraductal mass.
A. Contrast-enhanced pancreas CT scan obtained at arterial phase shows only moderate dilatation of main pancreatic duct (arrow) in tail
of pancreas, and there is no evidence of obstructive mass. Atrophy with decreased enhancement of pancreatic tail is due to chronic
pancreatitis.
B, C. T2-weighted (B) and gadolinium-enhanced (C) pancreas MR images show enhancing intraductal mass (short arrows) of main
pancreatic duct in pancreatic body with dilatation of upstream main pancreatic duct (long arrows).
D. MR cholangiopancretography shows filling defect (short arrows) that is due to intraductal mass with dilatation of upstream main
pancreatic duct (long arrow) and there is no dilatation of downstream main pancreatic duct.
E. Endoscopic retrograde pancreatogram shows filling defect (arrows) of contrast media that is due to mass in main pancreatic duct in
pancreatic body.
F. Photograph of resected specimen shows mass (arrow) in dilated main pancreatic duct.
EF(Figs. 1B, C) showed an enhancing mass in the dilated main
pancreatic duct of the pancreatic body, which resulted in
obstruction and dilatation of the upstream main pancreatic
duct, and this caused chronic pancreatitis. MRCP showed a
filling defect due to an intraductal mass with dilatation of
the upstream main pancreatic duct with no dilatation of the
downstream main pancreatic duct (Fig. 1D). An endoscopic
retrograde pancreatogram (Fig. 1E) showed a filling defect
of the contrast media due to a mass in the dilated, yet
patent main pancreatic duct. No hypersecretion of mucin
was noted.
Under the impression of a mass confined to the main
pancreatic duct of the pancreatic body, the patient
underwent a subtotal pancreatectomy. Macroscopically,
the tumor was 2.5 cm in the maximum diameter and it
filled the lumen of the main pancreatic duct (Fig. 1F).
Microscopically, the tumor was confined to the main
pancreatic duct with focal stromal invasion and the tumor
had an intraductal nodular appearance with a monotonous
tubular growth pattern, and there was no papillary projec-
tion or mucin hypersecretion. On the immunohistochemi-
cal staining, the tumor cells were diffusely positive for
MUC-1 and p53, and they were negative for MUC-2 and
MUC-5AC. The final diagnosis was a T1N0M0 stage ITC.
DISCUSSION
An ITC is an extremely rare pancreatic tumor (2) in the
pancreatic duct that shows a nodular or polypoid appear-
ance with a monotonous tubular growth pattern and it is
without papillary projection or mucin hypersecretion. On
immunohistochemical staining, ITC cells are positive for
MUC-1 and they are negative for MUC-2 and MUC-5AC.
However, intraductal papillary mucinous carcinoma cells
are negative for MUC-1 and most cells are positive for
MUC-2 and MUC-5AC (3). There may be two different
pathways for the development of an ITC: the “de novo”
and “adenoma-carcinoma sequence” pathways (4). 
Although the prognosis of an ITT is unclear, ITTs and
IPMNs are considered to have similar malignant potential
(9). ITTs may have an invasive component and/or they
have involvement in lymph node metastasis, and so the
prognosis of ITT is ghastly (9). ITCs are considered to be
more favorable when compared with a pancreatic ductal
adenocarcinoma (9). Therefore, early detection and
appropriate surgical resection are crucial to achieve long-
term survival in patients with an ITC.
As in the present case, MR imaging with MRCP together
with CT and an endoscopic retrograde pancreatogram are
very useful for diagnosing an intraductal tumor of the
pancreas. However, on the imaging findings, making the
diagnosis of ITC from the imaging findings can be confused
with that of an IPMN, and especially for the main duct
type IPMN because of the similar imaging findings such as
dilatation of the pancreatic duct and the presence of an
intraductal mass, in addition to the pancreatitis-like
symptoms (10). Based on the imaging findings of the
present case, the imaging finding of an IPMN shows the
dilatation of mainly the downstream main pancreatic duct,
which is caused by the hypersecretion of mucin. In contrast
ITC results in obstructive dilatation of the upstream main
pancreatic duct with no radiological or endoscopic
evidence of mucin hypersecretion. For the radiological
differentiation of ITCs from ITAs, intraductal growth that
completely occupies the dilated portion of the pancreatic
duct with large size may favor an ITC. Yet it was difficult
to differentiate between ITAs and ITCs in the present case
and this was also difficult to do in the previous reports (4,
6, 10). A further study with a large series is needed to
resolve this issue.
In conclusion, an ITC should be recognized as another
entity of an intraductal tumor of the pancreas that is
morphologically and immunohistochemically different
from an IPMN. An ITC should be included in the differen-
tial diagnosis when an intraductal mass that causes obstruc-
tive dilatation of the upstream main pancreatic duct has no
radiological or endoscopic evidence of mucin hypersecre-
tion. 
References
1. Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal
papillary mucinous neoplasms of the pancreas. In: Hamilton SR,
Aaltonen LA. Pathology and genetics of tumours of the
digestive system. WHO classification of tumours. Lyon: IARC
Press, 2000:237-240
2. Japan Pancreas Society. General Rules for the Study of
Pancreatic Cancer, 2nd ed. Tokyo: Kanehara, 2002
3. Tajiri T, Tate G, Inagaki T, Kunimura T, Inoue K, Mitsuya T, et
al. Intraductal tubular neoplasms of the pancreas: histogenesis
and differentiation. Pancreas 2005;30:115-121
4. Itatsu K, Sano T, Hiraoka N, Ojima H, Takahashi Y, Sakamoto
Y, et al. Intraductal tubular carcinoma in an adenoma of the
main pancreatic duct of the pancreas head. J Gastroenterol
2006;41:702-705
5. Tajiri T, Tate G, Kunimura T, Inoue K, Mitsuya T, Yoshiba M, et
al. Histologic and immunohistochemical comparison of intraduc-
tal tubular carcinoma, intraductal papillary-mucinous
carcinoma, and ductal adenocarcinoma of the pancreas.
Pancreas 2004;29:116-122
6. Ito K, Fujita N, Noda Y, Kobayashi G, Kimura K, Horaguchi J,
et al. Intraductal tubular adenocarcinoma of the pancreas
diagnosed before surgery by transpapillary biopsy: case report
and review. Gastrointest Endosc 2005;61:325-329
7. Thirot-Bidault A, Lazure T, Ples R, Dimet S, Dhalluin-Venier V,
Fabre M, et al. Pancreatic intraductal tubular carcinoma: a sub-
group of intraductal papillary-mucinous tumors or a distinct
Imaging of Intraductal Tubular Carcinoma of Pancreas
Korean J Radiol 9(5), October 2008 475entity? A case report and review of the literature. Gastroenterol
Clin Biol 2006;30:1301-1304
8. Hisa T, Nobukawa B, Suda K, Ohkubo H, Shiozawa S, Ishigame
H, et al. Intraductal carcinoma with complex fusion of tubular
glands without macroscopic mucus in main pancreatic duct:
dilemma in classification. Pathol Int 2007;57:741-745
9. Suda K, Hirai S, Matsumoto Y, Mogaki M, Oyama T, Mitsui T,
et al. Variant of intraductal carcinoma (with scant mucin produc-
tion) is of main pancreatic duct origin: a clinicopathological
study of four patients. Am J Gastroenterol 1996;91:798-800
10. Albores-Saavedra J, Sheahan K, O’Riain C, Shukla D.
Intraductal tubular adenoma, pyloric type, of the pancreas:
additional observations on a new type of pancreatic neoplasm.
Am J Surg Pathol 2004;28:233-238
Oh et al.
476 Korean J Radiol 9(5), October 2008